OSE Immunotherapeutics Extends Cash Runway as Key Trials Face Delays — OSE Immunotherapeutics SA

Event summary

OSE Immunotherapeutics reported €11.1 million in cash as of June 30, 2026, down from €17.0 million in March 2026, with runway extended to December 2026 via bridge financing.
Phase 3 trial ARTEMIA for Tedopi in lung cancer on track for completion by December 2026, but futility analysis delayed to early 2027 due to fewer death events than expected.
Subcutaneous formulation of lusvertikimab (IL-7R) on track for validation by mid-2027, with potential Phase 2 trial in chronic pouchitis in 2027.
First-half 2026 financial results postponed amid ongoing financing efforts with institutional investors in the U.S. and Europe.

The big picture

OSE Immunotherapeutics is navigating a critical financing phase while managing clinical trial timelines that could significantly impact its valuation. The biotech’s ability to extend its cash runway and deliver positive trial results will be key to attracting further investment in a competitive immuno-oncology and immuno-inflammation landscape. The company’s strategic focus on high-unmet-need indications like chronic pouchitis and ulcerative colitis positions it within broader trends toward precision therapies in inflammatory diseases.

What we're watching

Financing Strategy: Whether OSE can secure additional financing beyond December 2026 to support its 3-year strategic plan amid ongoing investor discussions.
Trial Timelines: The impact of the delayed futility analysis for Tedopi’s Phase 3 trial on regulatory approval timelines and investor confidence.
Pipeline Progress: The pace at which lusvertikimab’s subcutaneous formulation advances through clinical development and its potential market positioning in inflammatory bowel diseases.